Jayme M Heim, MSN, FNP-BC

Lauren Miller, MPAS, PA-C; Jayme M. Heim, MSN FNP-BC, and Kirk Gautier, PA-C, discuss recent advancements in plaque psoriasis treatment, focusing on novel oral systemic therapies like the TYK-2 inhibitor deucravacitinib and its clinical trial data, to inform therapeutic decisions for this systemic disease.

Lauren Miller, MPAS, PA-C; Jayme M. Heim, MSN FNP-BC, and Kirk Gautier, PA-C, discuss recent advancements in plaque psoriasis treatment, focusing on novel oral systemic therapies like the TYK-2 inhibitor deucravacitinib and its clinical trial data, to inform therapeutic decisions for this systemic disease.

Lauren Miller, MPAS, PA-C, leads an expert discussion surrounding exciting developments in the treatment landscape of plaque psoriasis.

Advanced practice providers in dermatology discuss exciting developments in the treatment landscape of plaque psoriasis. Listen to their insights into the often-challenging journey patients go on. The arrival of novel oral systemic treatment options offers opportunities to alleviate the burden of this chronic disease.

Advanced practice providers in dermatology discuss exciting developments in the treatment landscape of plaque psoriasis. Listen to their insights into the often-challenging journey patients go on. The arrival of novel oral systemic treatment options offers opportunities to alleviate the burden of this chronic disease.

Experts share practice pearls for managing patients with plaque psoriasis, highlighting the need to educate health care providers about any dermatologic therapy before they commit to treating a patient.

Experts discuss access to treatment as one of the biggest barriers in plaque psoriasis and highlight the importance of individualizing therapy for each patient.

Experts in dermatology comment on tapinarof and roflumilast, 2 nonsteroidal topical therapies recently approved for treatment of plaque psoriasis.

An expert shares considerations for choosing between an oral therapy and a biologic injection when treating plaque psoriasis.

Lauren Miller, MPAS, PA-C; and Jayme Heim, MSN, FNP-BC, share approaches to implementing the newly approved TYK2 inhibitor, deucravacitinib, into the treatment algorithm of plaque psoriasis.

Jayme Heim, MSN, FNP-BC, compares the efficacy, safety and dosing of 2 oral therapies, apremilast and deucravacitinib, for the treatment of plaque psoriasis.

Experts in dermatology review the efficacy and safety of deucravacitinib in the treatment of plaque psoriasis, a recently approved oral TYK2 inhibitor.

Jayme Heim, MSN, FNP-BC; and Lauren Miller, MPAS, PA-C, share thoughts on the use of oral systemic and biologic treatments in plaque psoriasis, commenting on the need for personalized care for patients.

An expert nurse practitioner comments on recent advances in the treatment of plaque psoriasis, as well as the continuous need for more treatment options.

Lauren Miller, MPAS, PA-C; and Jayme Heim, MSN, FNP-BC, discuss the role of advanced practice providers (APPs) within dermatology, highlighting the medical, surgical, and cosmetic categories in the space.

Experts in dermatology share practice pearls to advanced practice providers and community dermatologists for the management of plaque psoriasis.

Jayme M. Heim, MSN, FNP-BC, discusses unmet needs in the treatment landscape of plaque psoriasis.

Douglas DiRuggiero, DMSc, PA-C, reviews how deucravacitinib impacts the quality of life for patients with plaque psoriasis.

Darren West, MPAS, PA-C, shares how often follow-up is required with deucravacitinib therapy in plaque psoriasis.

Andrea Nguyen, PA-C, MS, provides an overview of the safety considerations of deucravacitinib for the treatment of plaque psoriasis.

Jayme Heim, MSN, FNP-BC, and Matthew T. Reynolds, PA-C, shares clinical pearls for clinicians managing patients with plaque psoriasis.

Matthew T. Reynolds, PA-C, comments on how evaluating treatment profiles, comorbidities, age, and population can help the clinician understand plaque psoriasis and improve management strategies.

Jayme Heim, MSN, FNP-BC, and Matthew T. Reynolds, PA-C, discuss implications of real-world data on the use of IL-23 inhibitors in treatment of plaque psoriasis for older patients.

Experts in dermatology discuss what patients to consider treating with deucravacitinib, as well as comment on the comparative safety and efficacy of other therapies.

Experts in dermatology discuss the importance of deucravacitinib being an expansion of oral treatment modalities for plaque psoriasis, as well as the long-term data.

Experts in psoriasis examine the implications of long-term data for IL-23 inhibitors, especially in patients who have not responded to initial treatment of plaque psoriasis.

Jayme Heim, MSN, FNP-BC, and Matthew T. Reynolds, PA-C, comment on potential safety concerns and adverse events regarding the use of IL-23 inhibitors as well as the long-term safety and efficacy of these therapies in plaque psoriasis.

Jayme M. Heim, MSN, FNP-BC, reviews deucravacitinib as an oral treatment for moderate to severe plaque psoriasis, describing its unique mechanism of action.

Douglas DiRuggiero, DMSc, PA-C, discusses factors that contribute to switching a patient with plaque psoriasis from a topical to a systemic agent.

Matthew T. Reynolds, PA-C, reviews the route of administration and dosing frequencies of current/approved IL-23 inhibitors tildrakizumab, guselkumab, and risankizumab for treatment of plaque psoriasis.